English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: Botox®, a preparation of botulinum toxin type A, is most widely used for blepharospasm (BPS) and hemifacial spasm (HFS). In this study, we present 82 patients who have been treated with Botox®. Material and Methods: This retrospective study included 15 BPS and 67 HFS patients who admitted to our clinic between May 2007 and December 2011. Botox® was diluted by sterile saline to adjust the dose to 5U/0.1 ml before injection. Pretarsal administration was applied. The average dose of Botox® required for an optimal response was 30-35 MU for BPS, 25-30 MU for HFS. Results: The therapeutic effect started after 3 to 5 days, and initial repetitive efficacy intervals (REI) [2nd REI, BPS (13,9 months) and HFS (5,8 months)] were longer than the last mean REI [7th REI, BPS (5.9 months) and HFS (3.7 months)], and there were statistically significant differences between BPS and HFS groups (p<0.05). The treatment was effective in both BPS and HFS. Adverse effects occurred in 7.29% of the injection series. Conclusion: BTX-A is established as an effective and safe agent in the treatment of BPS and HFS. The side effects of BTA-X administration may be reduced with the help of injection material used and the application technique.

Efficacy and Safety of Botulinum Toxin Type A (Botox®)' in Blepharospasm and Hemifacial Spasm